William Blair Has Negative Estimate for OCUL Q2 Earnings
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) – Investment analysts at William Blair reduced their Q2 2025 earnings estimates for Ocular Therapeutix in a research report issued to clients and investors on Monday, May 5th. William Blair analyst L. Hanbury-Brown now expects that the biopharmaceutical company will post earnings per share of ($0.35) for the […]
Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) – Investment analysts at William Blair reduced their Q2 2025 earnings estimates for Ocular Therapeutix in a research report issued to clients and investors on Monday, May 5th. William Blair analyst L. Hanbury-Brown now expects that the biopharmaceutical company will post earnings per share of ($0.35) for the […]
